1. Figure 3 Response after appearance of a new lesion
in a 56-year-old woman with metastatic melanoma treated with ipilimumab3
Figure 3 | Response after appearance of a new lesion in a 56-year-old woman with metastatic melanoma treated with ipilimumab3. Contrast-enhanced CT scans of the abdomen a | before and b | 12 weeks after initiation of ipilimumab therapy revealed new subcutaneous nodule (arrow), suspected to be a new site of metastasis. c | A follow-up CT scan 24 weeks after initiation of therapy revealed resolution of the nodule, indicating response after appearance of a new lesion. Reprinted with permission from Nishino, M. et al. Personalized tumor response assessment in the era of molecular medicine: cancer-specific and therapy-specific response criteria to complement pitfalls of RECIST. AJR Am. J. Roentgenol. 198, 737–745 (2012).
Nishino, M. et al. (2017) Monitoring immune-checkpoint blockade: response evaluation and biomarker development
Nat. Rev. Clin. Oncol. doi: /nrclinonc